Orphanet: VENICE I: Open Label, Single Arm, Phase 3B, Multi Center Study Evaluating the Efficacy of Venetoclax ABT 199 in RelapsedRefractory Subjects with Chronic Lymphocytic Leukemia CLL including those with the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment with a B Cell Receptor Inhibitor
x

Pesquisar uma rede

* (*) campo(s) de preenchimento obrigatório

VENICE I: Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) including those with the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment with a B-Cell Receptor Inhibitor

VENICE I: Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) including those with the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment with a B-Cell Receptor Inhibitor

  • Tipo de rede : Ensaios clínicos multinacionais
  • Cobertura geográfica : Global
  • Entidade(s) financiadora(s) : -
  • Promotor : ABBVIE DEUTSCHLAND GMBH & CO. KG
  • Website
  • Coordenador de ensaio clínico multinacional

  • INFORMATION NOT PROVIDED
  • AbbVie Deutschland GmbH & Co. KG
  • Mainzer Straße 81
  • 65189 WIESBADEN
  • ALEMANHA
  • Mais informação
  • Contacto telefónico  : 49 (0) 611 1720 0
  • Fax  : 49 (0) 611 1720 1244
  • Website
  • Contact secretary  :
Atualizado em: Novembro 2019

Participantes

Informação adicional

Os documentos contidos neste website são apresentação para efeitos apenas de informação. O material não substitui os cuidados médicos profissinais por um especialista profissional qualificado e não deve ser usado como base para diagnóstico ou tratamento.